CD47 and myelodysplastic syndrome: However, in 2019, a clinical trial about the combination treatment of the CD47 antibody and azacytidine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) indicated high treatment efficacy and high ADRs (Sallman et al., 2019).